These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

• J7668

  Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligrams

• J7669

  Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams

• J7670

  Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams

• J7674

  Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg

• J7676

  Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg

• J7677

  Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram

• J7680

  Terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram

• J7681

  Terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

• J7682

  Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams

• J7683

  Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram

• J7684

  Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

• J7685

  Tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligrams

• J7686

  Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg

• J7699

  Noc drugs, inhalation solution administered through dme

• J7799

  Noc drugs, other than inhalation drugs, administered through dme

• J7999

  Compounded drug, not otherwise classified

• J8498

  Antiemetic drug, rectal/suppository, not otherwise specified

• J8499

  Prescription drug, oral, non chemotherapeutic, nos

• J8501

  Aprepitant, oral, 5 mg

• J8502

  Injection, aprepitant (aponvie), 1 mg

• J8510

  Busulfan; oral, 2 mg

• J8515

  Cabergoline, oral, 0.25 mg

• J8520

  Capecitabine, oral, 150 mg

• J8521

  Capecitabine, oral, 500 mg

• J8522

  Capecitabine, oral, 50 mg

• J8530

  Cyclophosphamide; oral, 25 mg

• J8540

  Dexamethasone, oral, 0.25 mg

• J8541

  Dexamethasone (hemady), oral, 0.25 mg

• J8560

  Etoposide; oral, 50 mg

• J8562

  Fludarabine phosphate, oral, 10 mg

• J8565

  Gefitinib, oral, 250 mg

• J8597

  Antiemetic drug, oral, not otherwise specified

• J8600

  Melphalan; oral, 2 mg

• J8610

  Methotrexate; oral, 2.5 mg

• J8611

  Methotrexate (jylamvo), oral, 2.5 mg

• J8612

  Methotrexate (xatmep), oral, 2.5 mg

• J8650

  Nabilone, oral, 1 mg

• J8655

  Netupitant 300 mg and palonosetron 0.5 mg, oral

• J8670

  Rolapitant, oral, 1 mg

• J8700

  Temozolomide, oral, 5 mg

• J8705

  Topotecan, oral, 0.25 mg

• J8999

  Prescription drug, oral, chemotherapeutic, nos

• J9000

  Injection, doxorubicin hydrochloride, 10 mg

• J9003

  Leuprolide injectable (camcevi etm), 1 mg

• J9010

  Injection, alemtuzumab, 10 mg

• J9011

  Injection, datopotamab deruxtecan-dlnk, 1 mg

• J9015

  Injection, aldesleukin, per single use vial

• J9017

  Injection, arsenic trioxide, 1 mg

• J9019

  Injection, asparaginase (erwinaze), 1,000 iu

• J9020

  Injection, asparaginase, not otherwise specified, 10,000 units

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/4/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.